205

Last update : 09/05/2017

Episurvey Hepatite B - A cross-sectional, multicentre, epidemiological study of the drug management in hepatitis B

Head : Bregman Bruno, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Main objective

Describe the drug management of patients having chronic hepatitis B, in France, in 2006.

Inclusion criteria

M/F >=18 years, infected by the hepatitis B virus for at least 6 months, seen in outpatient clinic visit at expert centers for caring of hepatitis (Hepatitis Referenced University Hospitals, General Hospital Centres, community-based hepato-gastroenterologists) between 1 Jan. and 31 March 2006.

Last update : 09/05/2017

EMPATHIE - Enfants - Parents - Trouble déficit de l’attention avec Hyperactivité : Impact et Evaluation

Head : Ponthieux Anne

Version 1

206

Last update : 12/01/2018

EMPATHIE - Enfants - Parents - Trouble déficit de l’attention avec Hyperactivité : Impact et Evaluation

Head : Ponthieux Anne

Main objective

Study of the impact of the Attention-Deficit Hyperactivity Disorder (ADHD) on the parents/tutors of afflicted school children.
The study also strives to evaluate the impact of the ADHD on the siblings of the children afflicted and likewise of the impact of the disease on the school environment, thanks to the evidence provided by parents/tutors.

Inclusion criteria

Inclusion criteria for parents/tutors:
- Parents (father, mother or tutors) of a child aged 6 to 18 years suffering from ADHD
- Parents (father, mother, or tutors) accompanying their ADHD children for a routine consultation during the observation period,
- Parent (father, mother or tutor) of an child whether or not treated for his/her ADHD.

Inclusion criteria for siblings:
- Brother or sister without ADHD of a child corresponding to the aforementioned criteria,
- Brother or sister at least 9 years old and living with the ADHD child.

Non-inclusion criteria :
- ADHD child with important co-morbidity that could influence assessment of ADHD impact on psycho-socio-economic value,
- Patients sibling / parents with important co-morbidity that could influence the evaluation of their experience (i.e. at the level of the socio-psycho-economic impact),
- Parents unable to complete a self-questionnaire,
- Parents who participated to the feasability study (interviews)

Last update : 12/01/2018

KARU-PROSTATE - Case-Control Study on the Impact of Chlordecone Exposure and Risk of Prostate Cancer in the West Indies

Head : Multigner Luc , U1085 Research Institute of Health, Environment and Work

Version 1

207

Last update : 09/05/2017

KARU-PROSTATE - Case-Control Study on the Impact of Chlordecone Exposure and Risk of Prostate Cancer in the West Indies

Head : Multigner Luc , U1085 Research Institute of Health, Environment and Work

Main objective

To identify the environmental and genetic risk factors of prostate cancer and to assess the impact of chlordecone exposure in the onset of the disease.

Inclusion criteria

– Male
– Adult
– Caribbean native (Guadeloupe, Martinique, Haiti, Dominica)

Last update : 09/05/2017

EUROPOP - European programme on the relationship between occupational risks and premature births

Head : Ancel Pierre-Yves, U953 - Unité de recherche épidémiologique en santé périnatale et santé des femmes et des enfants

Version 1

208

Last update : 09/05/2017

EUROPOP - European programme on the relationship between occupational risks and premature births

Head : Ancel Pierre-Yves, U953 - Unité de recherche épidémiologique en santé périnatale et santé des femmes et des enfants

Main objective

Consider the effect of particular work conditions on premature birth.

Inclusion criteria

woman - adult - childbirth 22-36 weeks amenorrhea

Last update : 09/05/2017

DOREMI - Factors influencing the motivation of the unbalanced type-2 diabetic obese patient in monotherapy by oral diabetes medication

Head : VIGNAL Franck, Sanofi Aventis

Version 1

209

Last update : 01/01/2018

DOREMI - Factors influencing the motivation of the unbalanced type-2 diabetic obese patient in monotherapy by oral diabetes medication

Head : VIGNAL Franck, Sanofi Aventis

Main objective

Describe the factors influencing the motivation of the unbalanced type-2 diabetic obese patient in monotherapy by oral diabetes medication in adhering to the drug and hygiene and dietary care of its cardiometabolic risk factors.

Inclusion criteria

Man or woman over the age of 18 years, Type-2 diabetes treated via oral diabetes medication monotherapy, Having a HbA1c rate ≥ 6.5%, A BMI ≥ 30 kg/m2, An abdominal obesity defined according to the NCEP/ATPIII criteria: Waist > 88 cm for women and > 102 cm for men,
Able to understand simple recommendations in terms of physical activity and complete a self-evaluation questionnaire

Last update : 01/01/2018

AEPEI - Repeated Cross-Sectional Study from The Association for The Study and Prevention of Infective Endocarditis

Head : Duval Xavier, CIC7 CIC BICHAT Recherche clinique : Cardio-vasculaire, pneumologie, diabétologie, maladies infectieusesU738 Modèles et méthodes de l'évaluation thérapeutique des maladies chroniquesÉquipe: Modélisation biostatistique et pharmacométrie

Version 1

210

Last update : 12/01/2018

AEPEI - Repeated Cross-Sectional Study from The Association for The Study and Prevention of Infective Endocarditis

Head : Duval Xavier, CIC7 CIC BICHAT Recherche clinique : Cardio-vasculaire, pneumologie, diabétologie, maladies infectieusesU738 Modèles et méthodes de l'évaluation thérapeutique des maladies chroniquesÉquipe: Modélisation biostatistique et pharmacométrie

Main objective

To describe trends in incidence, epidemiological, clinical, microbiological and prognostic factors, as well as surgical treatment procedures for infective endocarditis in France in 2008, in relation to 1991 and 1999.

Inclusion criteria

- Male and female;
- Over 18 years old;
- Treated for infective endocarditis.

Last update : 12/01/2018